EnClear Therapies, a Cambridge, MA-based early-stage neurotechnology company, raised additional funding.
Backers included Brain Tumor Investment Fund and the Sontag Innovation Fund and existing investors such as Amgen Ventures, Founders Fund, Thiel Bio Fund, Tachyon Ventures, and BioVerge Fund.
The company intends to use the funds to expedite the development of its technology within the Neuro-Oncology field, bolstering pre-clinical programs aimed at transforming the treatment landscape for central nervous system diseases.
Led by CEO Anthony DePasqua, EnClear Therapies is dedicated to providing solutions for central nervous system diseases through innovative neurotechnological strategies. Their flagship product, the EnTrega CSF management platform, leverages advancements to optimize therapeutic delivery and patient care in neuro-oncology and beyond.
This achievement follows the receipt of over $5M in non-dilutive funding through Small Business Innovation Research (SBIR) grants from the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), as well as strategic partnerships within the pharmaceutical sector.
FinSMEs
04/09/2024